ZIM Laboratories

₹134.52As of Sun 8 Nov 2026, 12:00 UTC
NSE:ZIMLABHealthcare
Country India
PE (Fwd) 96.42
TSR 4Y CAGR 6.43%
Div yield —
ROE —
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 0.82
PE TTM 112.9
TSR TTM 83.67%
Mkt cap ₹7.294B
ROIC —
SE Grade™
Value
Quality
Moat
1Y Price
Reference
₹150
11.15%
(89.00%)
Price above Reference Value
FY23
FY24
FY25
FY26
Earnings per share₹
5.01
3.54
2.50
1.19
67.77%
(29.35%)
(29.46%)
(52.34%)
Revenue₹B
3.986
3.675
3.790
3.744
19.52%
(7.80%)
3.13%
(1.22%)
TTM
FYE 31 Mar INR
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
FY2027E
Trend
5Y
10Y
Peers
3.744
Revenue₹B
—
—
—
—
—
3.335
3.986
3.675
3.790
3.744
3.948
2.93%
2.93%
32
(1.22)
Revenue growth%
—
—
—
—
—
—
19.52
(7.80)
3.13
(1.22)
5.44
0.96
—
64
52.74
Gross margin%
—
—
—
—
—
49.93
48.01
50.60
53.62
52.74
52.68
50.60
50.60
68
2.75
Operating margin%
—
—
—
—
—
7.51
8.85
6.98
6.46
2.75
2.79
6.98
6.98
29
1.56
Net margin%
—
—
—
—
—
4.36
6.13
4.69
3.21
1.56
1.61
4.36
4.36
32
112.9
P/E ratio (avg)x
—
—
—
—
—
—
18.23
34.09
43.71
70.11
103.4
38.90
—
10
63.97
EV/EBITx
—
—
—
—
—
—
12.63
22.90
21.73
39.74
59.76
22.32
—
5
—
FCF yield (avg)%
—
—
—
—
—
—
—
—
—
—
—
—
—
24
—
FCF margin%
—
—
—
—
—
—
—
—
—
—
—
—
—
24
—
FCF / Net incomex
—
—
—
—
—
—
—
—
—
—
—
—
—
0
—
ROIC%
—
—
—
—
—
—
—
—
—
—
—
—
—
37
—
Return on equity%
—
—
—
—
—
—
—
—
—
—
—
—
—
38
—
Return on assets%
—
—
—
—
—
—
—
—
—
—
—
—
—
43
1.19
EPS₹
—
—
—
—
—
2.99
5.01
3.54
2.50
1.19
1.30
(20.51%)
(20.51%)
—
(52.26)
EPS growth%
—
—
—
—
—
—
67.93
(29.42)
(29.46)
(52.26)
9.17
(29.44)
—
6
—
Bookvalue per sh₹
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
FCF per share₹
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
Dividend per sh₹
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
Div yield (avg)%
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
Payout ratio%
—
—
—
—
—
—
—
—
—
—
—
—
—
—
48.98
Shares (diluted)M
—
—
—
—
—
◇48.73
48.73
48.73
48.73
48.98
◌48.98
0.13%
0.13%
24
(0.52)
Buyback yield%
—
—
—
—
—
—
—
—
—
(0.52)
◌—
—
—
24
—
D/E ratiox
—
—
—
—
—
—
—
—
—
—
—
—
—
28
6.589
Enterprise value₹B
—
—
—
—
—
—
4.454
5.879
5.317
4.093
6.589
(2.78%)
—
60
—
LT debt₹M
—
—
—
—
—
—
—
—
—
—
—
—
—
50
Peers (US$74.98M)
Cap (US$)
PE
80.74M
38.99x
74.06M
14.35x
Capital
TTM
5Y
10Y
Leveragex
—
—
—
EBIT/Intx
0.853
3.491
3.491
Own earn%
—
—
—
Sh yield%
(0.52)
—
—
Owners
Insiders/Inst%
53.94
1.18
Short interest%
—
SBC / revenue%
0.26
Record
10Y
Profitable years
5/5
Revenue growth years
2/4
EPS growth years
1/4
Dividend streakyrs
0
Op margin range%
3–9
$1 testx
—
Incr. ROIC%
—

ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. It provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, directly compressible granules, tablets, capsules, dry syrup, and oral thin films.

Growth vs revenue
Latest
Trend
4Y CAGR
Rel growth
Revenue
₹3.744B
2.93%
1.00×
Cost of revenue
₹1.770B
1.46%
0.94×
Operating expenses
₹1.871B
7.24%
1.18×
Revenue by region
No breakdown available
Reinvestment returns
n/m
Trend
Reinvestment rate
n/m
-
Return on capital
n/m
-
Spread over hurdle
n/m
-